EP1082320A4 - Novel substituted imidazole compounds - Google Patents

Novel substituted imidazole compounds

Info

Publication number
EP1082320A4
EP1082320A4 EP99924480A EP99924480A EP1082320A4 EP 1082320 A4 EP1082320 A4 EP 1082320A4 EP 99924480 A EP99924480 A EP 99924480A EP 99924480 A EP99924480 A EP 99924480A EP 1082320 A4 EP1082320 A4 EP 1082320A4
Authority
EP
European Patent Office
Prior art keywords
imidazole compounds
substituted imidazole
novel substituted
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99924480A
Other languages
German (de)
French (fr)
Other versions
EP1082320A1 (en
Inventor
Jerry Leroy Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1082320A1 publication Critical patent/EP1082320A1/en
Publication of EP1082320A4 publication Critical patent/EP1082320A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
EP99924480A 1998-05-26 1999-05-25 Novel substituted imidazole compounds Withdrawn EP1082320A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8664598P 1998-05-26 1998-05-26
US86645P 1998-05-26
PCT/US1999/011455 WO1999061440A1 (en) 1998-05-26 1999-05-25 Novel substituted imidazole compounds

Publications (2)

Publication Number Publication Date
EP1082320A1 EP1082320A1 (en) 2001-03-14
EP1082320A4 true EP1082320A4 (en) 2001-11-21

Family

ID=22199934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99924480A Withdrawn EP1082320A4 (en) 1998-05-26 1999-05-25 Novel substituted imidazole compounds

Country Status (4)

Country Link
EP (1) EP1082320A4 (en)
JP (1) JP2002516325A (en)
CA (1) CA2333157A1 (en)
WO (1) WO1999061440A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
HUP0104693A3 (en) * 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
ES2230171T3 (en) 1999-11-23 2005-05-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSBP / P38 QUINASA INHIBITORS.
WO2002022610A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
ES2251582T3 (en) 2001-03-09 2006-05-01 Pfizer Products Inc. BENCIMIDAZOL ANTI-INFLAMMATORY COMPOUNDS.
CZ20032185A3 (en) 2001-03-09 2004-06-16 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
EP1247810B1 (en) 2001-04-04 2005-09-07 Pfizer Products Inc. Novel benzotriazoles anti-inflammatory compounds
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP2006508051A (en) 2002-08-29 2006-03-09 サイオス インク． How to promote bone formation
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
PA8579601A1 (en) 2002-08-30 2004-05-07 Pfizer Prod Inc ANTIINFLAMMATORY COMPOUNDS OF DI AND TRIFLORURO-TRIAZOLO-PIRIDINAS
ES2324165T3 (en) * 2003-02-26 2009-07-31 Kowa Co., Ltd. TREATMENT OF ALLERGIC CONTACT DERMATITIS.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20060166936A1 (en) * 2004-10-29 2006-07-27 Hayley Binch Diaminotriazole compounds useful as inhibitors of protein kinases
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CN102245765B (en) 2008-10-21 2015-01-07 通用医院公司 Cell transplantation
MX2011010401A (en) * 2009-04-01 2012-01-20 Rappaport Family Inst Res In The Medical Sciences A method of regulating proliferation and differentiation of keratinocyes.
CN103153376B (en) 2010-08-06 2018-04-20 通用医院公司以麻省总医院名义经营 System and apparatus for cell processing related applications
CN113518779B (en) 2019-03-28 2024-03-15 江苏恒瑞医药股份有限公司 Thieno heterocyclic derivative, preparation method and medical application thereof
US20220185818A1 (en) 2019-03-29 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
TW202110848A (en) 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 A substituted fused bicyclic derivative, a preparation method thereof, and medical applications thereof
EP4223758A4 (en) 2020-09-29 2024-04-03 Jiangsu Hengrui Pharmaceuticals Co Ltd Crystal form of pyrrolo heterocyclic derivative and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016230A1 (en) * 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016230A1 (en) * 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACKSON J R ET AL: "Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 284, no. 2, 1998, pages 687 - 692, XP002134931, ISSN: 0022-3565 *
See also references of WO9961440A1 *

Also Published As

Publication number Publication date
CA2333157A1 (en) 1999-12-02
JP2002516325A (en) 2002-06-04
WO1999061440A1 (en) 1999-12-02
EP1082320A1 (en) 2001-03-14

Similar Documents

Publication Publication Date Title
EP1082320A4 (en) Novel substituted imidazole compounds
ZA985764B (en) Novel substituted imidazole compounds
IL125282A0 (en) Novel substituted imidazole compounds
IL133035A0 (en) Novel substituted imidazole compounds
IL139732A0 (en) Novel 2-alkyl substituted imidazole compounds
AP9701008A0 (en) Novel substituted imidazole compounds
SI0935465T1 (en) Novel substituted imidazole compounds
AUPP484098A0 (en) Novel imidazole compounds
AUPP735598A0 (en) Novel imidazole compounds
GB9802658D0 (en) Novel compounds
GB9802644D0 (en) Novel compounds
GB9802801D0 (en) Novel compounds
GB9802798D0 (en) Novel compounds
GB9802795D0 (en) Novel compounds
GB9802698D0 (en) Novel compounds
GB9802665D0 (en) Novel compounds
GB9802661D0 (en) Novel compounds
GB9802659D0 (en) Novel compounds
GB9802664D0 (en) Novel compounds
GB9802657D0 (en) Novel compounds
GB9802656D0 (en) Novel compounds
GB9802655D0 (en) Novel compounds
GB9802654D0 (en) Novel compounds
GB9802653D0 (en) Novel compounds
GB9802646D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 403/14 A, 7C 07D 413/14 B, 7A 61K 31/505 B, 7A 61K 31/535 B, 7C 07D 403/04 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011221